The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The average age of men who get diagnosed is 67.

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...

A retired Winnipeg teacher who raised money for his own prostate cancer treatment after learning that provincial health ...